aluates Reports

$ 0.0

Automative

Global Urokinase for Injection Market Research Report 2026

Published Date: 2026-01-14

Report Code: QYRE-Auto-4E9798

Global Urokinase for Injection Market Insights and Forecast to 2028

BUY CHAPTERS

Global Urokinase for Injection Market Research Report 2026

Code: QYRE-Auto-4E9798

Report

2026-01-14

Pages:115

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Wanhua Biochem

Jiangxi Haoran Bio-Pharma

Jiangsu Aidea Pharmaceutical

Wuhan Humanwell Pharma

Tianjin Biochem Pharma

Urokinase for Injection Market Size

The global Urokinase for Injection market was valued at US$ 313 million in 2025 and is anticipated to reach US$ 476 million by 2032, at a CAGR of 6.3% from 2026 to 2032.

Urokinase for Injection Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Urokinase for Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

The urokinase injection market refers to the clinical and commercial use of injectable urokinase (urokinase for injection)—a “clot-dissolving” medicine used in hospitals to break down unwanted blood clots. Urokinase works by acting on the body’s natural fibrinolytic system: it converts plasminogen into plasmin, and plasmin then breaks down fibrin clots (and also affects fibrinogen and some other plasma proteins). Because urokinase is given by injection/infusion and can cause serious bleeding, its use is typically limited to settings where doctors can monitor patients closely (emergency departments, intensive care units, catheter labs, interventional radiology suites, vascular surgery wards, and specialized stroke or thrombosis centers).

In practical terms, the market is defined by where and how urokinase injection is used. In some jurisdictions, product labeling and clinical practice include use for pulmonary embolism (blood clots in the lungs), for catheter-directed thrombolysis in peripheral arteries or graft occlusions, and for restoring patency of intravenous catheters blocked by clotted blood or fibrin. This “hospital procedure drug” positioning is important: urokinase injection is not a long-term prevention drug like oral anticoagulants; it is more often a time-sensitive rescue therapy or a procedure-support drug used when a clot is already causing acute risk or blocking a device.

A key part of the market definition is also the dosage form and supply chain. Urokinase products are commonly supplied as a sterile lyophilized (freeze-dried) powder that must be reconstituted before use. These factors make urokinase different from many small-molecule injectables: producers must manage complex upstream cell culture, purification, sterile fill-finish, and strict quality control, and buyers care about lot consistency and supply reliability.

In 2025, global Urokinase for Injection production reached approximately 15.6 million Units, with an average global market price of around US$ 20.1 per Units. The global single-line production capacity ranges from 350 to 500 K Units per year. The industry's gross profit margin is approximately 25%-35%.

On market trends, one broad trend is that thrombolysis is being shaped by newer thrombolytic agents, improved imaging, and more interventional procedures. In acute ischemic stroke, for example, many global guidelines focus on intravenous alteplase (and increasingly tenecteplase as an alternative in some systems) within defined time windows, and mechanical thrombectomy has expanded in selected patients. This matters for urokinase because it changes where urokinase is positioned: in many countries, urokinase is not the primary stroke thrombolytic, while in others it is used as a lower-cost or locally available option. A recent review notes that urokinase has been approved and used in China for years and that Chinese guidance has recommended intravenous urokinase within certain time windows for acute ischemic stroke, with commonly cited dosing ranges (for example 1,000,000–1,500,000 IU in that context). So, the stroke segment shows a “two-track” trend: in some regions, practice is consolidating around rt-PA/tenecteplase and thrombectomy pathways, while in other regions, urokinase remains relevant due to access, cost, and local evidence bases.

A second trend is the growth of catheter use in modern medicine, which tends to expand the catheter-clearance opportunity for thrombolytics, including urokinase. Central venous catheters and other long-term lines are widely used for chemotherapy, parenteral nutrition, long courses of IV antibiotics, and repeated blood draws. The clinical literature describes catheter occlusion as a frequent complication and reviews thrombolytic options for restoring patency. In that review, several thrombolytic agents (including recombinant urokinase) are discussed with reported catheter clearance rates and time-to-clearance outcomes, and the paper also notes that thrombolytic prophylaxis in some studies reduced catheter occlusion incidence. Even if individual studies vary, the practical market implication is straightforward: as the number of patients dependent on long-term catheters rises (cancer care, home infusion, complex pediatrics, dialysis pathways), hospitals place higher value on reliable, fast methods to reopen lines and avoid line replacement procedures.

A third trend is a procedural shift toward targeted therapy in vascular care. For some vascular occlusions, clinicians may prefer catheter-directed approaches that localize treatment at the clot, often aiming to improve efficacy while limiting systemic exposure and bleeding risk. Urokinase has a history of use in catheter-directed settings (for example, peripheral arterial and graft thromboembolic occlusion described in product monographs). At the same time, competition is intense: other thrombolytics (alteplase, tenecteplase, reteplase in certain contexts) and mechanical strategies (aspiration, thrombectomy devices, angioplasty/stenting) all influence whether a hospital uses urokinase, which dose, and for which patients. This competitive pressure pushes the urokinase market toward niches where it has clear operational or economic advantages (availability, protocol familiarity, cost, or suitability for a specific catheter-clearance workflow).

This report delivers a comprehensive overview of the global Urokinase for Injection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Urokinase for Injection. The Urokinase for Injection market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Urokinase for Injection market comprehensively. Regional market sizes by Type, by Application, by Clinical Use, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Urokinase for Injection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Urokinase for Injection Market Report

Report Metric	Details
Report Name	Urokinase for Injection Market
Accounted market size in 2025	US$ 313 million
Forecasted market size in 2032	US$ 476 million
CAGR	6.3%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	10000-100000IU 100000-1000000IU Others
Segment by Clinical Use	Pulmonary Embolism Thrombolysis Deep Vein Thrombosis Peripheral Arterial Occlusion Thrombolysis Catheter / Cannula Occlusion Clearance Others
Segment by Administration Approach	Systemic Infusion Catheter-directed Thrombolysis (CDT) Intracatheter Dwell / Lock Technique
Segment by Purity	Standard Clinical Grade High-purity / Low-impurity Grade Low Endotoxin / Low Bioburden Specifications
by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Clinical Use, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Urokinase for Injection manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Urokinase for Injection sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Urokinase for Injection Market growing?

Ans: The Urokinase for Injection Market witnessing a CAGR of 6.3% during the forecast period 2026-2032.

What is the Urokinase for Injection Market size in 2032?

Ans: The Urokinase for Injection Market size in 2032 will be US$ 476 million.

Who are the main players in the Urokinase for Injection Market report?

Ans: The main players in the Urokinase for Injection Market are Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma

What are the Application segmentation covered in the Urokinase for Injection Market report?

Ans: The Applications covered in the Urokinase for Injection Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Urokinase for Injection Market report?

Ans: The Types covered in the Urokinase for Injection Market report are 10000-100000IU, 100000-1000000IU, Others

1 Urokinase for Injection Market Overview

1.1 Product Definition

1.2 Urokinase for Injection by Type

1.2.1 Global Urokinase for Injection Market Value by Type: 2025 vs 2032

1.2.2 10000-100000IU

1.2.3 100000-1000000IU

1.2.4 Others

1.3 Urokinase for Injection by Clinical Use

1.3.1 Global Urokinase for Injection Market Value by Clinical Use: 2025 vs 2032

1.3.2 Pulmonary Embolism Thrombolysis

1.3.3 Deep Vein Thrombosis

1.3.4 Peripheral Arterial Occlusion Thrombolysis

1.3.5 Catheter / Cannula Occlusion Clearance

1.3.6 Others

1.4 Urokinase for Injection by Administration Approach

1.4.1 Global Urokinase for Injection Market Value by Administration Approach: 2025 vs 2032

1.4.2 Systemic Infusion

1.4.3 Catheter-directed Thrombolysis (CDT)

1.4.4 Intracatheter Dwell / Lock Technique

1.5 Urokinase for Injection by Purity

1.5.1 Global Urokinase for Injection Market Value by Purity: 2025 vs 2032

1.5.2 Standard Clinical Grade

1.5.3 High-purity / Low-impurity Grade

1.5.4 Low Endotoxin / Low Bioburden Specifications

1.6 Urokinase for Injection by Application

1.6.1 Global Urokinase for Injection Market Value by Application: 2025 vs 2032

1.6.2 Hospital

1.6.3 Clinic

1.6.4 Others

1.7 Global Urokinase for Injection Market Size Estimates and Forecasts

1.7.1 Global Urokinase for Injection Revenue 2021–2032

1.7.2 Global Urokinase for Injection Sales 2021–2032

1.7.3 Global Urokinase for Injection Market Average Price (2021–2032)

1.8 Assumptions and Limitations

2 Urokinase for Injection Market Competition by Manufacturers

2.1 Global Urokinase for Injection Sales Market Share by Manufacturers (2021–2026)

2.2 Global Urokinase for Injection Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Urokinase for Injection Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Urokinase for Injection, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Urokinase for Injection, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Urokinase for Injection, Product Types and Applications

2.7 Global Key Manufacturers of Urokinase for Injection, Date of Entry into the Industry

2.8 Global Urokinase for Injection Market Competitive Situation and Trends

2.8.1 Global Urokinase for Injection Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Urokinase for Injection Players Market Share by Revenue

2.8.3 Global Urokinase for Injection Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Urokinase for Injection Market Scenario by Region

3.1 Global Urokinase for Injection Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Urokinase for Injection Sales by Region: 2021–2032

3.2.1 Global Urokinase for Injection Sales by Region: 2021–2026

3.2.2 Global Urokinase for Injection Sales by Region: 2027–2032

3.3 Global Urokinase for Injection Revenue by Region: 2021–2032

3.3.1 Global Urokinase for Injection Revenue by Region: 2021–2026

3.3.2 Global Urokinase for Injection Revenue by Region: 2027–2032

3.4 North America Urokinase for Injection Market Facts & Figures by Country

3.4.1 North America Urokinase for Injection Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Urokinase for Injection Sales by Country (2021–2032)

3.4.3 North America Urokinase for Injection Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Urokinase for Injection Market Facts & Figures by Country

3.5.1 Europe Urokinase for Injection Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Urokinase for Injection Sales by Country (2021–2032)

3.5.3 Europe Urokinase for Injection Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Urokinase for Injection Market Facts & Figures by Region

3.6.1 Asia Pacific Urokinase for Injection Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Urokinase for Injection Sales by Region (2021–2032)

3.6.3 Asia Pacific Urokinase for Injection Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Urokinase for Injection Market Facts & Figures by Country

3.7.1 Latin America Urokinase for Injection Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Urokinase for Injection Sales by Country (2021–2032)

3.7.3 Latin America Urokinase for Injection Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Urokinase for Injection Market Facts & Figures by Country

3.8.1 Middle East and Africa Urokinase for Injection Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Urokinase for Injection Sales by Country (2021–2032)

3.8.3 Middle East and Africa Urokinase for Injection Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Urokinase for Injection Sales by Type (2021–2032)

4.1.1 Global Urokinase for Injection Sales by Type (2021–2026)

4.1.2 Global Urokinase for Injection Sales by Type (2027–2032)

4.1.3 Global Urokinase for Injection Sales Market Share by Type (2021–2032)

4.2 Global Urokinase for Injection Revenue by Type (2021–2032)

4.2.1 Global Urokinase for Injection Revenue by Type (2021–2026)

4.2.2 Global Urokinase for Injection Revenue by Type (2027–2032)

4.2.3 Global Urokinase for Injection Revenue Market Share by Type (2021–2032)

4.3 Global Urokinase for Injection Price by Type (2021–2032)

5 Segment by Application

5.1 Global Urokinase for Injection Sales by Application (2021–2032)

5.1.1 Global Urokinase for Injection Sales by Application (2021–2026)

5.1.2 Global Urokinase for Injection Sales by Application (2027–2032)

5.1.3 Global Urokinase for Injection Sales Market Share by Application (2021–2032)

5.2 Global Urokinase for Injection Revenue by Application (2021–2032)

5.2.1 Global Urokinase for Injection Revenue by Application (2021–2026)

5.2.2 Global Urokinase for Injection Revenue by Application (2027–2032)

5.2.3 Global Urokinase for Injection Revenue Market Share by Application (2021–2032)

5.3 Global Urokinase for Injection Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Syner-Med

6.1.1 Syner-Med Company Information

6.1.2 Syner-Med Description and Business Overview

6.1.3 Syner-Med Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Syner-Med Urokinase for Injection Product Portfolio

6.1.5 Syner-Med Recent Developments/Updates

6.2 Wanhua Biochem

6.2.1 Wanhua Biochem Company Information

6.2.2 Wanhua Biochem Description and Business Overview

6.2.3 Wanhua Biochem Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Wanhua Biochem Urokinase for Injection Product Portfolio

6.2.5 Wanhua Biochem Recent Developments/Updates

6.3 Jiangxi Haoran Bio-Pharma

6.3.1 Jiangxi Haoran Bio-Pharma Company Information

6.3.2 Jiangxi Haoran Bio-Pharma Description and Business Overview

6.3.3 Jiangxi Haoran Bio-Pharma Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Jiangxi Haoran Bio-Pharma Urokinase for Injection Product Portfolio

6.3.5 Jiangxi Haoran Bio-Pharma Recent Developments/Updates

6.4 Jiangsu Aidea Pharmaceutical

6.4.1 Jiangsu Aidea Pharmaceutical Company Information

6.4.2 Jiangsu Aidea Pharmaceutical Description and Business Overview

6.4.3 Jiangsu Aidea Pharmaceutical Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Jiangsu Aidea Pharmaceutical Urokinase for Injection Product Portfolio

6.4.5 Jiangsu Aidea Pharmaceutical Recent Developments/Updates

6.5 Techpool

6.5.1 Techpool Company Information

6.5.2 Techpool Description and Business Overview

6.5.3 Techpool Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Techpool Urokinase for Injection Product Portfolio

6.5.5 Techpool Recent Developments/Updates

6.6 Microbic Biosystems

6.6.1 Microbic Biosystems Company Information

6.6.2 Microbic Biosystems Description and Business Overview

6.6.3 Microbic Biosystems Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Microbic Biosystems Urokinase for Injection Product Portfolio

6.6.5 Microbic Biosystems Recent Developments/Updates

6.7 LIVZON

6.7.1 LIVZON Company Information

6.7.2 LIVZON Description and Business Overview

6.7.3 LIVZON Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 LIVZON Urokinase for Injection Product Portfolio

6.7.5 LIVZON Recent Developments/Updates

6.8 Wuhan Humanwell Pharma

6.8.1 Wuhan Humanwell Pharma Company Information

6.8.2 Wuhan Humanwell Pharma Description and Business Overview

6.8.3 Wuhan Humanwell Pharma Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Wuhan Humanwell Pharma Urokinase for Injection Product Portfolio

6.8.5 Wuhan Humanwell Pharma Recent Developments/Updates

6.9 Tianjin Biochem Pharma

6.9.1 Tianjin Biochem Pharma Company Information

6.9.2 Tianjin Biochem Pharma Description and Business Overview

6.9.3 Tianjin Biochem Pharma Urokinase for Injection Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Tianjin Biochem Pharma Urokinase for Injection Product Portfolio

6.9.5 Tianjin Biochem Pharma Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Urokinase for Injection Industry Chain Analysis

7.2 Urokinase for Injection Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Urokinase for Injection Production Mode & Process Analysis

7.4 Urokinase for Injection Sales and Marketing

7.4.1 Urokinase for Injection Sales Channels

7.4.2 Urokinase for Injection Distributors

7.5 Urokinase for Injection Customer Analysis

8 Urokinase for Injection Market Dynamics

8.1 Urokinase for Injection Industry Trends

8.2 Urokinase for Injection Market Drivers

8.3 Urokinase for Injection Market Challenges

8.4 Urokinase for Injection Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Wanhua Biochem

Jiangxi Haoran Bio-Pharma

Jiangsu Aidea Pharmaceutical

Wuhan Humanwell Pharma

Tianjin Biochem Pharma

List of Tables

Table 1. Global Urokinase for Injection Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Urokinase for Injection Market Value by Clinical Use (US$ Million), 2025 vs 2032

Table 3. Global Urokinase for Injection Market Value by Administration Approach (US$ Million), 2025 vs 2032

Table 4. Global Urokinase for Injection Market Value by Purity (US$ Million), 2025 vs 2032

Table 5. Global Urokinase for Injection Market Value by Application (US$ Million), 2025 vs 2032

Table 6. Global Urokinase for Injection Market Competitive Situation by Manufacturers in 2025

Table 7. Global Urokinase for Injection Sales (K Units) of Key Manufacturers (2021–2026)

Table 8. Global Urokinase for Injection Sales Market Share by Manufacturers (2021–2026)

Table 9. Global Urokinase for Injection Revenue (US$ Million) by Manufacturers (2021–2026)

Table 10. Global Urokinase for Injection Revenue Share by Manufacturers (2021–2026)

Table 11. Global Market Urokinase for Injection Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 12. Global Key Players of Urokinase for Injection, Industry Ranking, 2023 vs 2024 vs 2025

Table 13. Global Key Manufacturers of Urokinase for Injection, Manufacturing Sites and Headquarters

Table 14. Global Key Manufacturers of Urokinase for Injection, Product Types and Applications

Table 15. Global Key Manufacturers of Urokinase for Injection, Date of Entry into the Industry

Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 17. Global Urokinase for Injection Companies by Tier (Tier 1, Tier 2, Tier 3), based on Urokinase for Injection Revenue, 2025

Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 19. Global Urokinase for Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 20. Global Urokinase for Injection Sales by Region (K Units), 2021–2026

Table 21. Global Urokinase for Injection Sales Market Share by Region (2021–2026)

Table 22. Global Urokinase for Injection Sales by Region (K Units), 2027–2032

Table 23. Global Urokinase for Injection Sales Market Share by Region (2027–2032)

Table 24. Global Urokinase for Injection Revenue by Region (US$ Million), 2021–2026

Table 25. Global Urokinase for Injection Revenue Market Share by Region (2021–2026)

Table 26. Global Urokinase for Injection Revenue by Region (US$ Million), 2027–2032

Table 27. Global Urokinase for Injection Revenue Market Share by Region (2027–2032)

Table 28. North America Urokinase for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 29. North America Urokinase for Injection Sales by Country (K Units), 2021–2026

Table 30. North America Urokinase for Injection Sales by Country (K Units), 2027–2032

Table 31. North America Urokinase for Injection Revenue by Country (US$ Million), 2021–2026

Table 32. North America Urokinase for Injection Revenue by Country (US$ Million), 2027–2032

Table 33. Europe Urokinase for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 34. Europe Urokinase for Injection Sales by Country (K Units), 2021–2026

Table 35. Europe Urokinase for Injection Sales by Country (K Units), 2027–2032

Table 36. Europe Urokinase for Injection Revenue by Country (US$ Million), 2021–2026

Table 37. Europe Urokinase for Injection Revenue by Country (US$ Million), 2027–2032

Table 38. Asia Pacific Urokinase for Injection Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 39. Asia Pacific Urokinase for Injection Sales by Region (K Units), 2021–2026

Table 40. Asia Pacific Urokinase for Injection Sales by Region (K Units), 2027–2032

Table 41. Asia Pacific Urokinase for Injection Revenue by Region (US$ Million), 2021–2026

Table 42. Asia Pacific Urokinase for Injection Revenue by Region (US$ Million), 2027–2032

Table 43. Latin America Urokinase for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 44. Latin America Urokinase for Injection Sales by Country (K Units), 2021–2026

Table 45. Latin America Urokinase for Injection Sales by Country (K Units), 2027–2032

Table 46. Latin America Urokinase for Injection Revenue by Country (US$ Million), 2021–2026

Table 47. Latin America Urokinase for Injection Revenue by Country (US$ Million), 2027–2032

Table 48. Middle East and Africa Urokinase for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 49. Middle East and Africa Urokinase for Injection Sales by Country (K Units), 2021–2026

Table 50. Middle East and Africa Urokinase for Injection Sales by Country (K Units), 2027–2032

Table 51. Middle East and Africa Urokinase for Injection Revenue by Country (US$ Million), 2021–2026

Table 52. Middle East and Africa Urokinase for Injection Revenue by Country (US$ Million), 2027–2032

Table 53. Global Urokinase for Injection Sales (K Units) by Type (2021–2026)

Table 54. Global Urokinase for Injection Sales (K Units) by Type (2027–2032)

Table 55. Global Urokinase for Injection Sales Market Share by Type (2021–2026)

Table 56. Global Urokinase for Injection Sales Market Share by Type (2027–2032)

Table 57. Global Urokinase for Injection Revenue (US$ Million) by Type (2021–2026)

Table 58. Global Urokinase for Injection Revenue (US$ Million) by Type (2027–2032)

Table 59. Global Urokinase for Injection Revenue Market Share by Type (2021–2026)

Table 60. Global Urokinase for Injection Revenue Market Share by Type (2027–2032)

Table 61. Global Urokinase for Injection Price (US$/Unit) by Type (2021–2026)

Table 62. Global Urokinase for Injection Price (US$/Unit) by Type (2027–2032)

Table 63. Global Urokinase for Injection Sales (K Units) by Application (2021–2026)

Table 64. Global Urokinase for Injection Sales (K Units) by Application (2027–2032)

Table 65. Global Urokinase for Injection Sales Market Share by Application (2021–2026)

Table 66. Global Urokinase for Injection Sales Market Share by Application (2027–2032)

Table 67. Global Urokinase for Injection Revenue (US$ Million) by Application (2021–2026)

Table 68. Global Urokinase for Injection Revenue (US$ Million) by Application (2027–2032)

Table 69. Global Urokinase for Injection Revenue Market Share by Application (2021–2026)

Table 70. Global Urokinase for Injection Revenue Market Share by Application (2027–2032)

Table 71. Global Urokinase for Injection Price (US$/Unit) by Application (2021–2026)

Table 72. Global Urokinase for Injection Price (US$/Unit) by Application (2027–2032)

Table 73. Syner-Med Company Information

Table 74. Syner-Med Description and Business Overview

Table 75. Syner-Med Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 76. Syner-Med Urokinase for Injection Product

Table 77. Syner-Med Recent Developments/Updates

Table 78. Wanhua Biochem Company Information

Table 79. Wanhua Biochem Description and Business Overview

Table 80. Wanhua Biochem Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 81. Wanhua Biochem Urokinase for Injection Product

Table 82. Wanhua Biochem Recent Developments/Updates

Table 83. Jiangxi Haoran Bio-Pharma Company Information

Table 84. Jiangxi Haoran Bio-Pharma Description and Business Overview

Table 85. Jiangxi Haoran Bio-Pharma Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 86. Jiangxi Haoran Bio-Pharma Urokinase for Injection Product

Table 87. Jiangxi Haoran Bio-Pharma Recent Developments/Updates

Table 88. Jiangsu Aidea Pharmaceutical Company Information

Table 89. Jiangsu Aidea Pharmaceutical Description and Business Overview

Table 90. Jiangsu Aidea Pharmaceutical Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 91. Jiangsu Aidea Pharmaceutical Urokinase for Injection Product

Table 92. Jiangsu Aidea Pharmaceutical Recent Developments/Updates

Table 93. Techpool Company Information

Table 94. Techpool Description and Business Overview

Table 95. Techpool Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 96. Techpool Urokinase for Injection Product

Table 97. Techpool Recent Developments/Updates

Table 98. Microbic Biosystems Company Information

Table 99. Microbic Biosystems Description and Business Overview

Table 100. Microbic Biosystems Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 101. Microbic Biosystems Urokinase for Injection Product

Table 102. Microbic Biosystems Recent Developments/Updates

Table 103. LIVZON Company Information

Table 104. LIVZON Description and Business Overview

Table 105. LIVZON Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 106. LIVZON Urokinase for Injection Product

Table 107. LIVZON Recent Developments/Updates

Table 108. Wuhan Humanwell Pharma Company Information

Table 109. Wuhan Humanwell Pharma Description and Business Overview

Table 110. Wuhan Humanwell Pharma Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 111. Wuhan Humanwell Pharma Urokinase for Injection Product

Table 112. Wuhan Humanwell Pharma Recent Developments/Updates

Table 113. Tianjin Biochem Pharma Company Information

Table 114. Tianjin Biochem Pharma Description and Business Overview

Table 115. Tianjin Biochem Pharma Urokinase for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 116. Tianjin Biochem Pharma Urokinase for Injection Product

Table 117. Tianjin Biochem Pharma Recent Developments/Updates

Table 118. Key Raw Materials Lists

Table 119. Raw Materials Key Suppliers Lists

Table 120. Urokinase for Injection Distributors List

Table 121. Urokinase for Injection Customers List

Table 122. Urokinase for Injection Market Trends

Table 123. Urokinase for Injection Market Drivers

Table 124. Urokinase for Injection Market Challenges

Table 125. Urokinase for Injection Market Restraints

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

Table 129. Authors List of This Report

List of Figures

Figure 1. Product Picture of Urokinase for Injection

Figure 2. Global Urokinase for Injection Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Urokinase for Injection Market Share by Type: 2025 & 2032

Figure 4. 10000-100000IU Product Picture

Figure 5. 100000-1000000IU Product Picture

Figure 6. Others Product Picture

Figure 7. Global Urokinase for Injection Market Value by Clinical Use (US$ Million), 2021–2032

Figure 8. Global Urokinase for Injection Market Share by Clinical Use: 2025 vs 2032

Figure 9. Pulmonary Embolism Thrombolysis Product Picture

Figure 10. Deep Vein Thrombosis Product Picture

Figure 11. Peripheral Arterial Occlusion Thrombolysis Product Picture

Figure 12. Catheter / Cannula Occlusion Clearance Product Picture

Figure 13. Others Product Picture

Figure 14. Global Urokinase for Injection Market Value by Administration Approach (US$ Million), 2021–2032

Figure 15. Global Urokinase for Injection Market Share by Administration Approach: 2025 vs 2032

Figure 16. Systemic Infusion Product Picture

Figure 17. Catheter-directed Thrombolysis (CDT) Product Picture

Figure 18. Intracatheter Dwell / Lock Technique Product Picture

Figure 19. Global Urokinase for Injection Market Value by Purity (US$ Million), 2021–2032

Figure 20. Global Urokinase for Injection Market Share by Purity: 2025 vs 2032

Figure 21. Standard Clinical Grade Product Picture

Figure 22. High-purity / Low-impurity Grade Product Picture

Figure 23. Low Endotoxin / Low Bioburden Specifications Product Picture

Figure 24. Global Urokinase for Injection Market Value by Application (US$ Million), 2021–2032

Figure 25. Global Urokinase for Injection Market Share by Application: 2025 & 2032

Figure 26. Hospital

Figure 27. Clinic

Figure 28. Others

Figure 29. Global Urokinase for Injection Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 30. Global Urokinase for Injection Market Size (US$ Million), 2021–2032

Figure 31. Global Urokinase for Injection Sales (K Units), 2021–2032

Figure 32. Global Urokinase for Injection Average Price (US$/Unit), 2021–2032

Figure 33. Urokinase for Injection Report Years Considered

Figure 34. Urokinase for Injection Sales Share by Manufacturers in 2025

Figure 35. Global Urokinase for Injection Revenue Share by Manufacturers in 2025

Figure 36. Top 5 and Top 10 Global Urokinase for Injection Players: Market Share by Revenue in Urokinase for Injection in 2025

Figure 37. Urokinase for Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 38. Global Urokinase for Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 39. North America Urokinase for Injection Sales Market Share by Country (2021–2032)

Figure 40. North America Urokinase for Injection Revenue Market Share by Country (2021–2032)

Figure 41. U.S. Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Canada Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Europe Urokinase for Injection Sales Market Share by Country (2021–2032)

Figure 44. Europe Urokinase for Injection Revenue Market Share by Country (2021–2032)

Figure 45. Germany Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. France Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. U.K. Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Italy Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Russia Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Asia Pacific Urokinase for Injection Sales Market Share by Region (2021–2032)

Figure 51. Asia Pacific Urokinase for Injection Revenue Market Share by Region (2021–2032)

Figure 52. China Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Japan Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. South Korea Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. India Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Australia Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Taiwan Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Indonesia Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. Thailand Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Malaysia Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 61. Philippines Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. Latin America Urokinase for Injection Sales Market Share by Country (2021–2032)

Figure 63. Latin America Urokinase for Injection Revenue Market Share by Country (2021–2032)

Figure 64. Mexico Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 65. Brazil Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 66. Argentina Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 67. Middle East and Africa Urokinase for Injection Sales Market Share by Country (2021–2032)

Figure 68. Middle East and Africa Urokinase for Injection Revenue Market Share by Country (2021–2032)

Figure 69. Turkey Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 70. Saudi Arabia Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 71. U.A.E Urokinase for Injection Revenue Growth Rate (US$ Million), 2021–2032

Figure 72. Global Sales Market Share of Urokinase for Injection by Type (2021–2032)

Figure 73. Global Revenue Market Share of Urokinase for Injection by Type (2021–2032)

Figure 74. Global Urokinase for Injection Price (US$/Unit) by Type (2021–2032)

Figure 75. Global Sales Market Share of Urokinase for Injection by Application (2021–2032)

Figure 76. Global Revenue Market Share of Urokinase for Injection by Application (2021–2032)

Figure 77. Global Urokinase for Injection Price (US$/Unit) by Application (2021–2032)

Figure 78. Urokinase for Injection Value Chain

Figure 79. Channels of Distribution (Direct Vs Distribution)

Figure 80. Bottom-up and Top-down Approaches for This Report

Figure 81. Data Triangulation

Figure 82. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Urokinase Market Research Report 2025

Global Urokinase Lyophilized Powder Market Research Report 2024

Global Specific Plasminogen Activator Market Research Report 2024

Global Urokinase Powder Market Research Report 2024

Global uPA ELISA Kits Market Research Report 2024

Global Enterokinase Market Research Report 2025

Global Non specific Plasminogen Activator Market Research Report 2024

Global Thrombolytic Drug Market Insights Forecast to 2030

Global Crude Urokinase Market Research Report 2024

Global Serine Protease Market Insights Forecast to 2030

Global Protease for Animal Feed Market Research Report 2024

Thrombin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Feed Protease Market Research Report 2024

Thrombolysis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intraoperative Ultrasound Market Insights Forecast to 2030

Streptokinase Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Industrial Proteases Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Recombinant Enterokinase Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pegademase Bovine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions